Harmony Biosciences Files Q2 2024 10-Q
Ticker: HRMY · Form: 10-Q · Filed: 2024-08-06T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
Related Tickers: HRMY
TL;DR
Harmony Biosciences (HRMY) Q2 10-Q filed. Financials updated.
AI Summary
Harmony Biosciences Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial performance and business operations. Key details regarding its pharmaceutical preparations business and financial structure are outlined in the filing.
Why It Matters
This filing provides investors with an update on Harmony Biosciences' financial health and operational status for the second quarter of 2024, impacting investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Harmony Biosciences faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Harmony Biosciences Holdings, Inc. (company) — Filer of the 10-Q
- 20240630 (date) — End of the reporting period
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
- 001-39450 (company_id) — SEC File Number
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
What is the Standard Industrial Classification code for Harmony Biosciences?
The Standard Industrial Classification code for Harmony Biosciences is 2834, which corresponds to Pharmaceutical Preparations.
What is the SEC File Number for Harmony Biosciences?
The SEC File Number for Harmony Biosciences is 001-39450.
When was this 10-Q filed?
This 10-Q was filed on August 6, 2024.
What is the company's fiscal year end?
The company's fiscal year end is December 31.
From the Filing
0001558370-24-010956.txt : 20240806 0001558370-24-010956.hdr.sgml : 20240806 20240806080033 ACCESSION NUMBER: 0001558370-24-010956 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240806 DATE AS OF CHANGE: 20240806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 241177160 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 10-Q 1 hrmy-20240630x10q.htm 10-Q http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember 0001802665 --12-31 Q2 false http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember 0 0 http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-06-30 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-01-01 2024-06-30 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2024-01-01 2024-03-31 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-01-01 2023-06-30 0001802665 hrmy:October2023ShareRepurchaseProgramMember 2023-01-01 2023-03-31 0001802665 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001802665 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001802665 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001802665 us-gaap:RetainedEarningsMember 2024-06-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001802665 us-gaap:RetainedEarningsMember 2024-03-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001802665 2024-03-31 0001802665 us-gaap:RetainedEarningsMember 2023-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001802665 us-gaap:RetainedEarningsMember 2023-06-30 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001802665 us-gaap:RetainedEarningsMember 2023-03-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001802665 2023-03-31 0001802665 us-gaap:RetainedEarningsMember 2022-12-31 0001802665 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001802665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001802665 us-gaap:CommonStockMember 2024-06-30 0001802665 us-gaap:CommonStockMember 2024-03-31 0001802665 us-gaap:CommonStockMember 2023-12-31 0001802665 us-gaap:CommonStockMember 2023-06-30 0001802665 us-gaap:CommonStockMember 2023-03-31 0001802665 us-gaap:CommonStockMember 2022-12-31 0001802665 us-gaap:StockAppreciationRightsSARSMember 2024-01-01 2024-06-30 0001802665 srt:MinimumMember 2023-01-01 2023-12-31 0001802665 srt:MaximumMember 20